Who gets access to the new assets?

PIF reported roughly $20 billion of committed capital with a $60–80 billion pipeline and 12 international asset managers licensed (six new in the past year), signaling sizable private-market expansion in Saudi Arabia. FII data shows stablecoins reached $300 billion in circulation and $33 trillion in annual transactions in 2025, highlighting material scale in on-chain finance. Panels flagged AI's uneven ROI (≈60% of CEOs expect returns but ~20% see them; one bank ran 400 AI experiments with a 90% failure rate) while pitching synthetic biology as a potential trillion-dollar asset class and noting Africa's young workforce and critical-minerals endowment as major investment opportunities.

Analysis

The conference narrative points to catalytic infrastructure and distribution shifts more than isolated sector booms — that favors firms building transaction and custody rails while destabilizing incumbents that monetize deposit float. Expect a slow-moving but compounding reallocation of low-cost retail and institutional funding into native digital products; even modest share capture (single-digit percent of retail deposits over 2-4 years) would force banks to reprice a meaningful portion of deposit-funded liabilities and compress NIM by tens of basis points.

Capital allocation models tied to sovereign-led market creation (e.g., partnerships with national wealth vehicles) create winner-take-most dynamics: managers who secure first-mover distribution and regulatory privilege will compound fee-bearing AUM, while late entrants face fee pressure and higher customer acquisition costs. That dynamic favors scalable, platform-like asset managers and infrastructure providers over traditional alpha-only shops — but also concentrates regulatory and political tail risk in those early partners.

Across technology vectors, two regime risks dominate the outlook. First, rails and product adoption are fragile to operational shocks and regulation: a high-profile stablecoin or tokenization failure or a swift tightening of reserve/regulatory requirements could revert flows within weeks-to-months. Second, synthetic biology and AI-enabled life-science innovations are asymmetric optionalities — commercialization timelines are multi-year and binary, so allocate as venture-like exposure rather than as near-term earnings drivers for public equities.

Key Decisions for Investors

• Buy GLXY via a 12-month call spread to capture infrastructure upside (initiate within 2 weeks, size 1.5–3% NAV). Rationale: asymmetric payoff if on-chain rails adoption continues; capped premium limits downside (target 3:1+ upside if adoption accelerates). Hedge with a 40–60% unrealized loss stop on premium paid.
• Execute a thematic pair: long GLXY (1% NAV equity) / short WFC (1% NAV equity) with a 3–9 month horizon. Rationale: structural funding-share shift benefits crypto infra provider vs retail-bank funding fragility; pair reduces market beta. Risk: regulatory shock could hurt both — trim at 20–30% adverse move and re-evaluate after major regulatory headlines.
• Buy WFC 6–9 month OTM puts sized 0.5% NAV as an asymmetric hedge against accelerated deposit flight and NIM compression. Rationale: targeted insurance against sudden re-pricing of retail deposits; limited cost for high-conviction tail protection. If bank funding volatility spikes, roll into longer-dated protection.
• Allocate 0.5–2% NAV to long-dated biotech optionality via XBI (12–24 month call spreads) to capture synthetic-biology re-rating as platform wins commercial proofs. Rationale: multi-year, binary upside if AI+bio platformization yields revenue-generating products; treat as venture-like position and size accordingly to total fund illiquid exposure.